About Molecular Insight Pharmaceuticals
Molecular Insight Pharmaceuticals is a Healthcare company based in Cambridge (United States) founded in 1997, and was acquired by Progenics in January 2013. Radiopharmaceuticals and molecular imaging agents for use in oncology. The company was acqui-hired. Its focus areas include Life Sciences, Oncology, In-Vitro Diagnostic Tests and Prostate Cancer. Its legal entity is MOLECULAR INSIGHT PHARMACEUTICALS INC. Its competitors include ImaginAb, MDxHealth and GenomeDx Biosciences; 2 of its 3 listed competitors have raised funding.
Company details
Molecular Insight Pharmaceuticals develops therapeutic radiopharmaceuticals and molecular imaging agents for use in oncology and cardiology. The company targets the development of a small-molecule chemistry platform to improve detection of primary and metastatic prostate cancer and to provide a systemic radiotherapy for relapsed and metastatic prostate cancer. Its products include technetium Tc 99m trofolastat, a clinical-stage molecular imaging agent for patients with metastatic prostate cancer; and 131I-MIP-1095, a prostate cancer therapy for systemic delivery of radiotherapy. As of January 18, 2013, Molecular Insight Pharmaceuticals operates as a subsidiary of Progenics Pharmaceuticals.
- Headquarters Cambridge, United States
- Stage Public
- SectorsHealthcare
- Website molecularinsight.com
- Acquired by Progenics (Jan 2013)
- Legal Name Molecular Insight Pharmaceuticals Inc
Funding Insights of Molecular Insight Pharmaceuticals
- Total Rounds 14
- Last Round Grant — $1.97M
- First Round $981,548
(Aug 2007)
- Investors Count 1
Latest 10 of 14 funding rounds of Molecular Insight Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2011 | $1.97M | Grant | – | – | |
| Sep 2010 | $2.2M | Grant | – | – | |
| Sep 2010 | $243,101 | Grant | – | – | |
| Aug 2010 | $243,101 | Grant | – | – | |
| Mar 2010 | $299,680 | Grant | – | – | |
| Sep 2009 | $1.62M | Grant | – | – | |
| Sep 2009 | $1.62M | Grant | – | – | |
| Jul 2009 | $1.7M | Grant | – | – | |
| Jun 2009 | $1.52M | Grant | – | – | |
| Jun 2009 | $180,916 | Grant | – | – |
2 investors in total: 2 institutional.
Investors in Molecular Insight Pharmaceuticals
Molecular Insight Pharmaceuticals has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include HHS and Progenics.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Public health and human services are overseen by HHS. | 1953 | hhs.gov | ||
Imaging compounds & targeted radiotherapies to detect and treat prostate cancer. | 1988 | progenics.com | United States |
Investor details for Molecular Insight Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Molecular Insight Pharmaceuticals
5 dated milestones of Molecular Insight Pharmaceuticals across 16 years, from founding to its latest funding, stage changes and deals.
- Founded Molecular Insight Pharmaceuticals is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $982K.
- Funding Latest funding round, Grant, of $2.0M.
- Exit Acquired by Progenics.
Competitors of Molecular Insight Pharmaceuticals
Molecular Insight Pharmaceuticals has 3 listed competitors in our database, 2 of them funded. They include ImaginAb, MDxHealth and GenomeDx Biosciences.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| imaginab.com | 2007 | Los Angeles, United States | $59.64M | 17 | ImaginAb is focused on developing advanced immuno-oncology imaging technologies. | |
| mdxhealth.com | 2003 | Irvine, United States | 174 | Epigenetic tests for personalized cancer assessment and treatment. | ||
| genomedx.com | 2008 | San Diego, United States | $69.75M | 159 | Genomic tests for urologic cancers are developed and commercialized. |
Detailed competitors of Molecular Insight Pharmaceuticals
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Imaging Diagnostics
3 companies that operate in the same segment as Molecular Insight Pharmaceuticals (Imaging Diagnostics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Handheld ultrasound devices are developed for whole-body medical imaging. | 2011 | Guilford, Connecticut, United States | USD 350 M | USD 97.61 M | 464 | |
Robotic microsurgical systems for endoscopy are developed. | 2007 | Redwood City, California, United States | USD 733.62 M | 91 | ||
Ultrasound images are analyzed via AI-based software provided by Exo. | 2015 | Redwood City, California, United States | USD 463.39 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Molecular Insight Pharmaceuticals
Molecular Insight Pharmaceuticals was founded in 1997 and raised its 1st funding round 10 years after it was founded.
Molecular Insight Pharmaceuticals is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Molecular Insight Pharmaceuticals develops therapeutic radiopharmaceuticals and molecular imaging agents for use in oncology and cardiology. The company targets the development of a small-molecule chemistry platform to improve detection of primary and metastatic prostate cancer and to provide a systemic radiotherapy for relapsed and metastatic prostate cancer. Its products include technetium Tc 99m trofolastat, a clinical-stage molecular imaging agent for patients with metastatic prostate cancer; and 131I-MIP-1095, a prostate cancer therapy for systemic delivery of radiotherapy. As of January 18, 2013, Molecular Insight Pharmaceuticals operates as a subsidiary of Progenics Pharmaceuticals.
Molecular Insight Pharmaceuticals's top competitors include ImaginAb, MDxHealth and GenomeDx Biosciences.
Molecular Insight Pharmaceuticals operates through Molecular Insight Pharmaceuticals Inc.
Yes. Molecular Insight Pharmaceuticals was acquired by Progenics in January 2013.